Slide 1: Financial Results Quarter Ended September 30, 2015
Financial Results Quarter Ended September 30, 2015
Slide 2: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 3: Conference Call Details
Conference Call Details Date : Tuesday, October 29, 2015 Time : 5:00 pm IST Primary Number: +91 22 3938 1071 Secondary Number: +91 22 6746 8354 6000 1221 Available in – Ahmedabad, Bengaluru, Chennai, Cochin, Delhi, Gurgaon, Hyderabad, Kolkata, Noida. Accessible from all major carriers except BSNL/MT
Slide 4: Q2'16 Results Analysis
el pl JUBHANT LIFESCIENCES Q2’16 Results Analysis
Slide 5: Income Statement – Q2'FY16
Income Statement – Q2’FY16 Particulars Q2'FY15 Q1'FY16 Q2'FY16 YoY Growth QoQ Growth (Rs Crs) (%) Total Income from Operations 1,371 1,459 1,463 7% 0% Total Expenditure 1,260 1,129 1,142 Other Income 26 4 4 EBITDA including Other Income 137 333 325 137% -2% Depreciation 69 70 75 Finance Cost 96 96 9
Slide 6: Financial Highlights – Q2'FY16
Financial Highlights – Q2’FY16 • Income from Operations at Rs. 1,463 Crore, up 7% YoY • Growth in Pharmaceuticals segment revenues led by strong performance in Specialty Pharmaceuticals; growth in Life Science Ingredients led by Specialty Intermediates and Nutritional Products • Geographical growth
Slide 7: Segmental Revenue Analysis – Q2'FY16
Segmental Revenue Analysis – Q2’FY16 Revenue (Rs. Crs.) Revenue YoY Growth QoQ Growth Segmental Revenue Analysis Q2'FY15 Q1'FY16 Q2'FY16 Mix (%) % % Pharmaceuticals 614 741 747 51% 22% 1% Life Science Ingredients 757 718 716 49% -5% 0% Income from Operations 1,371 1,459 1,463 100% 7% 0% • Pharmaceut
Slide 8: Company Revenue – Geography wise – Q2'FY16
Company Revenue – Geography wise – Q2’FY16 China and Geo-wise Revenue (Rs crs) Q2'FY15 Q1'FY16 Q2'FY16 Mix % YoY % ROW India 421 402 409 28% -3% 11.2% India Europe & 28.0% International 950 1,056 1,054 72% 11% Japan USA & Canada 513 618 615 42% 20% 18.7% Europe & Japan 272 254 274 19% 1% USA & China
Slide 9: Pharma Revenue – Geography wise – Q2'FY16
Pharma Revenue – Geography wise – Q2’FY16 Geo-wise Revenue (Rs crs) Q2'FY15 Q1'FY16 Q2'FY16 Mix % YoY % ROW 6.4% India 31 39 34 4% 9% Europe & India International 584 702 713 96% 22% Japan 4.5% 12.4% USA & Canada 453 568 573 77% 26% Europe & Japan 81 72 93 12% 14% USA & ROW 49 61 48 6% -2% Canada 76
Slide 10: Pharma Business Highlights – Q2'FY16
Pharma Business Highlights – Q2’FY 16 • 38 commercial APIs, including 24 in North America, 23 in Europe and 28 in ROW • Launched Azithromycin Monohydrate (Oral) and Rabeprazole APIs in US • 49 commercial Solid Dosage Formulations products, including 27 in North America, 29 in Europe and 27 in ROW •
Slide 11: LSI Revenue – Geography wise – Q2'FY16
LSI Revenue – Geography wise – Q2’FY16 China and Geo-wise Revenue (Rs crs) Q2'FY15 Q1'FY16 Q2'FY16 Mix % YoY % ROW India 391 363 375 52% -4% 16.3% International 366 355 341 48% -7% Europe, India Europe, North America and North 52.4% 251 232 224 31% -11% America and Japan China and ROW 115 123 116 16
Slide 12: LSI Business Highlights – Q2'FY16
LSI Business Highlights – Q2’FY 16 • New contracts received for Nutritional Products; Robust pricing witnessed during the quarter • New contracts signed after successful completion of key customer audits in Specialty Intermediates • Pyridine performance stable on Q-o-Q basis; Pricing pressures in Ch
Slide 13: Operating Expenditure Analysis – Q2'FY16
Operating Expenditure Analysis – Q2’FY16 % of % of % of YoY QoQ Expenses (Rs Crs) Q2 FY15 Q1 FY16 Q2 FY16 Sales Sales Sales Growth % Growth % Material Cost 606 44% 537 37% 530 36% -13% -1% Power & Fuel Cost 100 7% 102 7% 99 7% -1% -3% Employee Cost 271 20% 274 19% 285 19% 5% 4% Other Expenses 283 21
Slide 14: EBITDA Analysis – Q2'FY16
EBITDA Analysis – Q2’FY16 EBITDA (Rs. Crs) Business Segments Q2'FY15 Q1'FY16 Q2'FY16 YoY Growth % QoQ Growth % Pharmaceuticals 69 225 215 211% -5% Life Science Ingredients 62 121 118 92% -2% Less: Corp Expenses 6 -13 -9 Reported EBITDA 137 333 325 137% -2% Margins (%) YoY Variance (Bps) QoQ Variance
Slide 15: Half Yearly Results Analysis
Half Yearly Results Analysis 14 14
Slide 16: Income Statement – H1'FY16
Income Statement – H1’FY16 Particulars H1'FY15 H1'FY16 YoY Growth (Rs Crs) (%) Total Income from Operations 2,844 2,922 3% Total Expenditure 2,588 2,272 Other Income 31 8 EBITDA including Other Income 287 658 129% Depreciation 142 145 Finance Cost 174 194 Profit after Interest but before Exceptional
Slide 17: Financial Highlights – H1'FY16
Financial Highlights – H1’FY16 • Income from Operations at Rs. 2922 crs, grew 3% YoY • Growth in Pharmaceuticals segment revenues led by strong performance in Specialty Pharmaceuticals • Revenue from International markets grow 6% YoY with North America sales growing 23% YoY • EBITDA at Rs. 658 crs •
Slide 18: Segmental Revenue Analysis – H1'FY16
Segmental Revenue Analysis – H1’FY 16 Revenue (Rs. Crs.) Revenue Mix YoY Growth Segmental Revenue Analysis H1'FY15 H1'FY16 (%) % Pharmaceuticals 1,218 1,488 51% 22% Life Science Ingredients 1,626 1,434 49% -12% Income from Operations 2,844 2,922 100% 3% • Income from Operations at Rs. 2,922 crs, gro
Slide 19: Company Revenue – Geography wise – H1'FY16
Company Revenue – Geography wise- H1’FY16 ROW, 7.4% Geo-wise Revenue (Rs crs) H1'FY15 H1'FY16 Mix % YoY % India 851 811 28% -5% India, 4.9% International 1,994 2,110 72% 6% Europe & Japan, 11.0% USA & Canada 1,003 1,233 42% 23% Europe & Japan 599 529 18% -12% China and ROW 391 349 12% -11% USA & Can
Slide 20: Pharma Revenue – Geography wise – H1'FY16
Pharma Revenue – Geography wise- H1’FY16 Geo-wise Revenue (Rs crs) H1'FY15 H1'FY16 Mix % YoY % ROW, 7.4% India 59 73 5% 24% India, 4.9% International 1,160 1,415 95% 22% Europe & Japan, 11.0% USA & Canada 876 1,141 77% 30% Europe & Japan 186 164 11% -12% ROW 98 109 7% 12% USA & Canada, Income from O
Slide 21: LSI Revenue – Geography wise – H1'FY16
LSI Revenue – Geography wise- H1’FY16 Geo-wise Revenue (Rs crs) H1'FY15 H1'FY16 Mix % YoY % India 792 738 51% -7% China and ROW, 16.7% International 834 696 49% -17% India, Europe, North America 51.5% 540 456 32% -16% Europe, and Japan North China and ROW 293 239 17% -18% America and Japan, 31.8% In
Slide 22: Operating Expenditure Analysis – H1'FY16
Operating Expenditure Analysis – H1’FY16 Expenses (Rs Crs) H1'FY15 % of Sales H1'FY16 % of Sales YoY Growth % Material Cost 1326 47% 1067 37% -19% Power & Fuel Cost 199 7% 201 7% 1% Employee Cost 543 19% 559 19% 3% Other Expenses 520 18% 444 15% -15% Total Expenses 2588 91% 2272 78% -12% • Material
Slide 23: EBITDA Analysis H1'FY16
EBITDA Analysis H1’FY16 EBITDA (Rs. Crs) Business Segments H1'FY15 H1'FY16 YoY Growth % Pharmaceuticals 105 441 320% Life Science Ingredients 195 240 23% Less: Corp Expenses -13 -22 Reported EBITDA 287 658 129% EBITDA Margins (%) YoY Variance (Bps) Pharmaceuticals 8.6% 29.6% 2101 Life Science Ingred
Slide 24: Debt Profile
Debt Profile Particulars 31-Mar-15 30-Jun-15 30-Sep-15 Foreign Currency Loans ($ Mn) ($ Mn) ($ Mn) Standalone 105 90 80 Subsidiaries 338 356 338 Total 443 445 417 Rupee Loans (Rs. Crs) (Rs. Crs) (Rs. Crs) Standalone 1,513 1,466 1,421 Subsidiaries 509 485 552 Total 2,022 1,951 1,973 Gross Debt 4,790
Slide 25: Outlook
Outlook In FY 2016, Pharmaceuticals segment to drive revenue growth • Pharmaceuticals segment expected to drive growth on account of: • Growth in North America in the Specialty Pharmaceuticals business • Ramp up of operations at Spokane • Life Science Ingredients to deliver better margins compared
Slide 26: For more information
For more information For Investors: Ravi Agrawal Siddharth Rangnekar Jubilant Life Sciences Limited CDR India Ph: +91-120-436 1002 Ph: +91-22-6645 1209 E-mail: ravi_agrawal@jubl.com E-mail: siddharth@cdr-india.com For Media: Sudhakar Safaya Kanika Mittal Jubilant Life Sciences Limited Perfect Relati